Teva Pharmaceutical Industries Limited (TEVA) Stock

Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company specializing in the development, manufacturing, marketing, and distribution of a diverse portfolio of healthcare products. Operating across North America, Europe, and internationally, Teva is renowned for its extensive range of generic medicines, specialty pharmaceuticals, and biopharmaceuticals. The company's product offerings encompass sterile products, hormones, high-potency drugs, and cytotoxic substances, delivered in various forms such as tablets, capsules, injectables, and topical formulations including transdermal patches, ointments, and creams. Teva also plays a crucial role in the active pharmaceutical ingredient market.

With a strategic focus on therapeutic areas including central nervous system disorders, pain management, respiratory ailments, and oncology, Teva boasts a robust pipeline and notable product portfolio. Key innovations include Copaxone for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for neurological conditions like tardive dyskinesia. In respiratory care, Teva offers leading treatments such as ProAir and QVAR, addressing conditions like asthma and chronic obstructive pulmonary disease. The company also delivers essential oncology therapies such as Bendeka and Trisenox, contributing significantly to cancer treatment worldwide.

Founded in 1901 and headquartered in Tel Aviv-Yafo, Israel, Teva Pharmaceutical Industries Limited collaborates extensively within the industry to advance pharmaceutical technologies. Notably, it has partnered with MedinCell to develop long-acting injectable products, including a risperidone suspension for schizophrenia treatment. Teva's commitment to innovation, coupled with its global reach and comprehensive product line, underscores its pivotal role in improving patient outcomes and advancing healthcare globally.